文献速递角膜与眼表疾病眼外伤

腐霉性角膜炎的临床特征、危险因素及药物与手术干预结局

Clinical profile, risk factors and outcome of medical, surgical and adjunct interventions in patients with Pythiuminsidiosum keratitis.
PubMed 文献 · Br J Ophthalmol · 2018-09-11

这项回顾性干预研究纳入46例经PCR DNA测序确诊的腐霉性角膜炎患者,比较药物管理、治疗性穿透性角膜移植术(TPK)及手术辅助措施的管理选择。结果显示TPK术后约51.8%复发需再次手术,而术中联合辅助措施者复发率仅7.1%,药物管理/术后药物辅助未见获益。

要点

  • TPK是腐霉性角膜炎推荐的主要治疗方式,严重者需行眼内容物剜除术。
  • TPK术后复发率约51.8%,近半数需再次手术。
  • TPK术中联合冷冻±酒精等辅助措施复发率低(7.1%),可考虑纳入常规。

核心结论

  • 目前推荐的治疗腐霉性角膜炎的方法是手术性TPK,更差病例需眼内容物剜除术。
  • 本研究中药物管理或TPK术后药物辅助对复发或感染加重需再次手术无益处。
  • TPK术中辅助措施似有额外获益且复发风险低,可纳入常规诊疗。

研究设计与样本

  • 回顾性干预研究,纳入2014年1月至2017年7月经PCR DNA测序诊断的腐霉性角膜炎患者46例。
  • 干预分为药物管理(MM:局部阿奇霉素和利奈唑胺联合口服阿奇霉素)、手术(S:TPK)、手术辅助(SA:冷冻±酒精联合TPK)和药物辅助(MA:TPK后MM)。

主要发现

  • 初始治疗包括MM 1眼、SA 3眼和S 42眼。
  • MM+S组43眼中27眼复发;11眼需第二次TPK,10眼需附加SA,5眼行眼内容物剜除术。
  • TPK-1后8/43眼接受MA;1眼需第三次TPK。
  • 接受MA的所有眼均复发(100%);42眼中54次TPK(第1+2+3次)中28次复发(51.8%)。
  • 接受SA的14眼中1眼复发(7.1%)。

关键数值与推荐

  • 复发定义及具体判定标准原文未报告。
  • MM方案为局部阿奇霉素和利奈唑胺联合口服阿奇霉素。
  • SA为冷冻±酒精联合TPK。

临床怎么用

  • 腐霉性角膜炎应优先考虑TPK手术干预,严重病例可能需眼内容物剜除术。
  • TPK术中可考虑联合冷冻±酒精等辅助措施以降低复发风险。
  • 不推荐单独依赖药物管理或TPK术后药物辅助作为减少复发的手段。

局限性

  • 回顾性研究设计。
  • 样本量较小(46例)。
  • 原文未报告具体危险因素分析结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To report clinical profile and compare management options for Pythium keratitis. METHOD: Retrospective interventional study of 46 patients diagnosed as Pythium keratitis by PCR DNA sequencing from January 2014 to July 2017. Interventions were categorised into medical management (MM) (topical azithromycin and linezolid with oral azithromycin at presentation), surgery (S) (therapeutic penetrating keratoplasty, TPK), surgical adjunct (SA) (cryotherapy±alcohol with TPK) and medical adjunct (MA) (MM after TPK). RESULTS: Primary treatment included MM (1 eye), SA (3 eyes) and S (42 eyes). Recurrence occurred in 27/43 eyes (MM+S group). Second surgery (S) was required in 11 eyes (TPK-2), with additional procedures (SA) in 10 eyes and evisceration in five eyes. 8/43 eyes received MA after TPK-1. One eye required TPK-3. Recurrence occured in all eyes that received MA (100%) and in 28 of 54 TPKs (51.8%) (TPK 1+2+3) in 42 eyes. Recurrence was noted in 1/14 (7.1%) that underwent SA. CONCLUSION: The currently available and recommended treatment for Pythium keratitis is surgical by means of a TPK and in worse cases evisceration. In our study, MM/MA measures showed no benefit with recurrence or worsening of infection requiring resurgery. Almost 50% of TPKs had a recurrence requiring resurgery. However, adjunctive procedures during TPK appear to have additional benefit with low risk of recurrence and could be included as routine care.

来源:Br J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Agarwal S, Iyer G, Srinivasan B, et al. Clinical profile, risk factors and outcome of medical, surgical and adjunct interventions in patients with Pythiuminsidiosum keratitis. Br J Ophthalmol. 2018. PMID: 30206158. doi:10.1136/bjophthalmol-2017-311804

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。